

DAFTAR PUSTAKA

1. Kouchkovsky ID, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. *Blood Cancer J.* 2016;6:e441. Available from: <https://dx.doi.org/10.1038/bcj.2016.50>.
2. Ferlay J, Ervik M, Lam F, Colombet M, Pineros M, Znaor A, et al. Global Cancer Observatory: Cancer Today. International Agency of Research on Cancer. 2020. Available from: <https://gco.iarc.fr/today>.
3. Saultz JN, Garzon R. Acute myeloid leukemia: a concise review. *J Clin Med.* 2016;5(33):1–17.
4. Surveillance, epidemiology, and end results (SEER) program cancer stat facts: leukemia – acute myeloid leukemia (AML). 2018. Available from: <https://seer.cancer.gov/statfacts/html/amyl.html>.
5. Bewersdorf JP, Shallis RM, Wang R, Huntingston SF, Perreault S, Ma X, et al. Healthcare expenses for treatment of acute myeloid leukemia. *Expert Rev Hematol.* 2019; 12(8): 641–50.
6. Cerrano M, Itzykson R. New treatment options for acute myeloid leukemia in 2019. *Curr Oncol Rep.* 2019;21(16):1–12.
7. Moarii M, Papaemmanuil E. Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. *Hematology.* 2017:37–44.
8. O'Brien EC, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. *Adv Hematol.* 2014:1–15. Available from: <https://dx.doi.org/10.1155/2014/103175>.
9. Liu S, Cadoux-Hudson T, Schofield CJ. Isocitrate dehydrogenase variants in cancer – cellular consequences and therapeutic opportunities. *Curr Opin Chem Biol.* 2020;57:122–34.
10. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. *Cancer Discov.* 2013;3:730–41.
11. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. *Am J Hematol.* 2015;90(8):732–6.

12. Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. *Leukemia*. 2017;31:272–81.
13. Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P, et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. *Cell Stem Cell*. 2014;14:329–41.
14. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell*. 2010;18: 553–67.
15. Fathi AT, Wander SA, Faramand R, Emadi A. Biochemical, epigenetic and metabolic approacher to target IDH mutations in acute myeloid leukemia. *Semin Hematol*. 2015. Available from: <http://dx.doi.org/10.1053/j.seminhematol.2015.03.002>.
16. Lin J, Yao D, Qian J, Chen Q, Qian W, Li Y, et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. *Ann Hematol*. 2012; 91: 519–25.
17. Aref S, Areida EK, Aaal MF, Adam OM, El-Ghonemy MS, El-Baiomy MA, et al. Prevalence and clinical effect of IDH1 and IDH2 mutations among cytogenetically normal acute myeloid leukemia patients. *Clin Lymphoma Myeloma Leuk*. 2015. Available from: <http://dx.doi.org/10.1016/j.clml.2015.05.009>.
18. Boddu P, Takahashi K, Pemmaraju N, Daver N, Benton CB, Pierce S., et al. Influence of IDH on FLT3ITD status in newly diagnosed AML. *Leukemia*. 2017. Available from: <https://dx.doi.org/10.1038/leu.2017.244>.
19. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, et al. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. *Cancer*. 2012;118:2665–73.
20. Virijevic M, Karan-Djurasevic T, Marjanovic I, Tosic N, Mitrovic M, Djunic I, et al. Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic

and follow-up markers in patients with acute myeloid leukemia with normal karyotype. *Radiol Oncol.* 2016;50(4):385–93.

21. Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, Suzushima H, et al. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. *Eur J Haematol.* 2014;92:471–7.
22. Eriksson A, Lennartsson A, Lehmann S. Epigenetic aberrations in acute myeloid leukemia: early key events during leukemogenesis. *Exp Hematol.* 2015. Available from: <https://dx.doi.org/10.1016/j.exphem.2015.05.009>.
23. Kiyoi H, Yamaguchi H, Maeda Y, Yamauchi T. JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML). *Int J Hematol.* 2020. Available from: <https://doi.org/10.1007/s12185-020-02856-3>.
24. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. *Cancer.* 2006; 107(9): 2099–107.
25. Fiegl M. Epidemiology, pathogenesis, and etiology of acute leukemia. In: Hiddenman W, editor. *Handbook of Acute Leukemia*. Switzerland: Springer International Publishing; 2016. p 3–13.
26. Emadi A, Baer MR. Acute myeloid leukemia in adults. In: Greer J, Arber DA, Appelbaum FR, Rodgers GM, Glader B, Dispenzieri A, et al., editors. *Wintrobe's Clinical Hematology*. 14th Edition. Philadelphia: Wolters Kluwer; 2019. p 4935–5005.
27. Liesveld JL, Lichtman MA. Acute Myelogenous Leukemia. In: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et al., editors. *Williams Hematology*. 19th Edition. New York: McGraw Hill Education; 2016. p 1373–415.
28. Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attribute risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on global burden of disease study 2017. *J Hematol Oncol.* 2020;13(72):1–16.

29. Udupa MS, Babu KG, Babu MC, Lakshmaiah KC, Lokanatha D, Jacob AL, et al. Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia. *J Can Res Ther*. 2020;16:18–22.
30. Bullinger L, Dohner K, Dohner H. Genomics of acute myeloid leukemia diagnosis and pathways. *J Clin Oncol*. 2017;35:934–46.
31. Marcucci G, Bloomfield CD. Acute myeloid leukemia. In: Longo DL, Kasper D, Haliser S, Larryjameson J, Fauci A, editors. *Harrison's Hematology and Oncology*. 3rd Edition. New York: McGraw Hill Education; 2017. p 168–80.
32. Kurnianda J. Leukemia Mieloblastik Akut. Dalam: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF, editor (penyunting). *Buku Ajar Ilmu Penyakit Dalam*. Edisi ke-6. Jakarta: Interna Publishing; 2015. hal 2671–7.
33. Betz BL, Hess JL. Acute myeloid leukemia diagnosis in 21st century. *Arch Patol Lab Med*. 2010;134:1427–33.
34. Charrot S, Armes H, Rio-Machin A, Fitzgibbon J. AML through the prism of molecular genetics. *Br J Haematol*. 2020; 188: 49–62.
35. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia Version 2.2021. National Comprehensive Cancer Network. 2020.
36. Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. *Am J Hematol*. 2018; 93:1267–91.
37. Padilha SL, Souza EJ, Matos MC, Domino NR. Acute myeloid leukemia: survival analysis of patients at a university hospital of Parana. *Rev Bras Hemoter*. 2015;37(1):21–7.
38. DiNardo CD, Garcia-Manero G, Pierce S, Nazha A, Bieso-Ramos C, Jabbour E, et al. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). *Am J Hematol*. 2016;91(2):227–32.
39. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. *Annu Rev Genomics Hum Genet*. 2002;3:179–98.
40. Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer. *APMIS*. 2007; 115: 1039–59.
41. Esteller M. Epigenetic changes in cancer. *F1000 Biol Rep*. 2011; 3(9): 1–6.

42. Gutierrez SE, Romero-Oliva F. Epigenetic changes: a common theme in acute myelogenous leukemogenesis. *J Hematol Oncol*. 2013; 6(57): 1–14.
43. Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. *Blood*. 2016;127(1):42–52.
44. Koszarska M, Bors A, Feczko A, Meggyesi N, Batai A, Csomor J, et al. Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. *Leuk Lymphoma*. 2013; 54(5): 1028–35.
45. Mukherjee K, Vilcinkas A, Twyman RM. Insects as models to study the epigenetic basis of disease. *Prog Biophys Mol Biol*. 2015; 118: 69–78.
46. Nassereddine S, Lap CJ, Haroun F, Tabbara I. The role of mutant IDH1 and IDH2 inhibitors in treatment of acute myeloid leukemia. *Ann Hematol*. 2017. Available from: <https://doi.org/10.1007/s00277-3161-0>.
47. Bergaggio E, Piva R. Wild-type IDH enzymes as actionable targets for cancer therapy. *Cancers*. 2019; 11(563): 1–16.
48. Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer. *Cancer Cell*. 2018: 1–10.
49. Bruce-Brand C, Govender D. Gene of the month: IDH1. *J Clin Pathol*. 2020; 73: 611–5.
50. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. *J Natl Cancer Inst*. 2010;102:932–41.
51. Al-Khallaf H. Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight. *Al-Khallaf Cell Biosci*. 2017;7:1–18.
52. Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. *Future Oncol*. 2018:1–16.
53. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. *Trends Mol Med*. 2012; 16: 387–97.
54. Li S, Mason C, Melnick A. Genetic and epigenetic heterogeneity in acute myeloid leukemia. *Curr Opin Genet Dev*. 2016; 36: 100–6.
55. Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong W, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence

- in acute myeloid leukemia. *Nat Med.* 2015. Available from: <http://doi.org/10.1038/nm.3788>.
56. Chen J, Lai Y, Tsai H, Kuo C, Yen BL, Yeh S, et al. The oncometabolite R-2-hydroxyglutarate activates NF- κ B-dependent tumor-promoting stromal niche for acute myeloid leukemia cells. *Sci Rep.* 2016;6:32428. Available from: <http://doi.org/10.1038/srep32428>.
57. Ragon BK, DiNardo CD. Targeting IDH1 and IDH2 mutations in acute myeloid leukemia. *Curr Hematol Malig Rep.* 2017: 1–10.
58. Kernytsky A, Wang F, Hansen E, Schalm S, Straley K, Gliser C, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. *Blood.* 2015;125(2):296–303.
59. Sun Y, Chen B, Deshpande A. Epigenetic regulators in the development, maintenance, and therapeutic targeting of acute myeloid leukemia. *Front Oncol.* 2018;8(41):1–16.
60. Fathi AT, Sadrzadeh H, Berger DR, Ballen KK, Amrein PC, Attar EC, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. *Blood.* 2012;20(23):4649–52.
61. Amaya ML, Pollyea D. Targeting the IDH2 pathway in acute myeloid leukemia. *Clin Cancer Res.* 2018: 1–9.
62. Xu Q, Li Y, Lv N, Jing Y, Xu Y, Li Y, et al. Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis. *Clin Cancer Res.* 2017. Available from: <http://doi.org/10.1158/1078-0432.CCR-16-2628>.
63. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med.* 2016; 374(23): 2209–21.
64. Balss J, Thiede C, Bochtler T, Okun JG, Saadati M, Benner A, et al. Pretreatment D-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. *Leukemia.* 2016; 30: 782–8.

65. Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, et al. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. *Cancer*. 2019. Available from: <http://doi.org/10.1002/cncr.31729>.
66. ElNahass YH, Badawy RH, ElRefaey FA, Nooh HA, Ibrahim D, Nader HA, et al. IDH mutations in AML patients; a higher association with intermediate risk cytogenetics. *Asian Pac J Cancer Prev*. 2020; 21(3): 721–5.
67. Duchmann M, Micol J, Duployez N, Raffoux E, Thomas X, Marolleau J, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. *Blood*. 2021; 137(20): 2827–37.
68. DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. *Blood*. 2013; 121(24): 4917–24.
69. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. *Blood Rev*. 2019; 36: 70–87.
70. Heuser M, Ofran Y, Boissel N, Mauri B, Craddock C, Janssen J, et al. Acute myeloid leukemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2013; 24(suppl 6): vi138–43.
71. Sanderson RN, Johnson PRE, Moorman AV, Roman E, Willett E, Taylor PR, et al. Population-based demographic study of karyotypes in 1709 patients with adult acute myeloid leukemia. *Leukemia*. 2006; 20: 444–50.
72. Sierra M, Alonso A, Odero MD, Gonzalez MB, Lahortiga I, Perez JJ, et al. Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain. *Leuk Res*. 2006; 30: 943–8.
73. Bashasha SH, Kordofani AA, Osman IM, Musa OH, Altayb HN, Elmagbool BK. Prevalence of the different FAB subtype of acute myeloid leukemia related to hematological parameters in Sudanese. *J Hematol Blood Disord*. 2017; 3(1): 102.

74. Nakase K, Bradstock K, Sartor M, Gottlieb D, Byth K, Kita K, et al. Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult cases. *Leukemia*. 2000; 14: 163–8.
75. Ma QL, Wang JH, Wang YG, Hu C, Mu QT, Yu MX, et al. High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia. *Int J Cancer*. 2014. Available from: <http://doi.org/10.1002/ijc.29395>.
76. Kranendijk M, Struys EA, Gibson M, Wickenhagen WV, Abdenur JE, Buechner J, et al. Evidence for genetic heterogeneity in D-2-hydroxyglutaric aciduria. *Hum Mutat*. 2010; 31: 279–83.
77. Han J, Jackson D, Holm J, Turner K, Ashcraft P, Wang X, et al. Elevated D-2-hydroxyglutarate during colitis drives progression to colorectal cancer. *Proc. Natl. Acad. Sci. U.S.A.* 2018; 115(5): 1057–62.
78. Matsunaga H, Futakuchi-Tsuchida A, Takahashi M, Ishikawa T, Tsuji M, Ando O. IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells. *Biochem. Biophys. Res. Commun.* 2012; 423: 553–6.
79. Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros J, Luthra R. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. *Am J Clin Pathol*. 2011; 135: 35–45.
80. Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, et al. Persistent IDH1/2 mutation in remission can predict relapse in patients with acute myeloid leukemia. *Haematologica*. 2018. Available from: <http://doi.org/10.3324/haematol.2018.191148>.
81. Kishtagari A, Levine RL, Viny AD. Driver mutations in acute myeloid leukemia. *Curr Opin Hematol*. 2020; 27: 49–57.
82. Jung J, Cho BS, Kim HJ, Han E, Jang W, Han K, et al. Reclassification of acute myeloid leukemia according to the 2016 WHO classification. *Ann Lab Med*. 2019; 39: 311–6.

83. Greenwood MJ, Seftel MD, Richardson C, Barbaric D, Barnett MJ, Bruyere H, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. *Leuk Lymphoma*. 2006; 47(7): 1245–52.

